Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 12/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.46 |
| ▸ | FAP | Q12884 | 3/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.46 |
| ▸ | PREP | P48147 | 2/20 | 0.46 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19982029 | 1.00 | DPP4 (0.46) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL15203539 | 1.00 | DPP4 (0.46) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL111112 | 0.98 | DPP4 (0.47) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL1951493 | 0.98 | DPP4 (0.47) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL296935 | 0.98 | DPP4 (0.47) | DPP4DPP7DPP8FAPDPP9 | |
| Hydrochloric Acid SCHEMBL25318201 | 0.96 | DPP4 (0.46) | DPP4DPP7DPP8FAPDPP9 | |
| Hydrochloric Acid SCHEMBL9512282 | 0.96 | DPP4 (0.46) | DPP4DPP7DPP8FAPDPP9 | |
| Hydrochloric Acid SCHEMBL9512271 | 0.96 | DPP4 (0.46) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL9102765 | 0.93 | DPP4 (0.47) | DPP4DPP7DPP8FAPDPP9 | |
| SCHEMBL9102749 | 0.93 | DPP4 (0.47) | DPP4DPP7DPP8FAPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339635-A1 | CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM S. AUREUS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-10-29 | — | — | US | disclosed |
| US-10723770-B2 | Crystal structure of the large ribosomal subunit from S. aureus | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-07-28 | — | — | US | disclosed |
| US-20200131232-A1 | CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM S. AUREUS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-04-30 | — | — | US | disclosed |
| US-10556934-B2 | Crystal structure of the large ribosomal subunit from S. aureus | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-02-11 | — | — | US | disclosed |
| EP-3250585-B1 | CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM S. AUREUS | YEDA RES & DEV (IL) | 2019-08-14 | — | — | EP | disclosed |
| US-20180009853-A1 | CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM S. AUREUS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-01-11 | — | — | US | disclosed |
| EP-3250585-A1 | CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM S. AUREUS | Yeda Research and Development Co., Ltd. (IL) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016120868-A1 | CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM S. AUREUS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-08-04 | — | — | WO | disclosed |
| US-8624033-B2 | Pleuromutilins and process for the preparation of pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2014-01-07 | — | — | US | disclosed |
| US-20130053571-A1 | PLEUROMUTILINS AND PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2013-02-28 | — | — | US | disclosed |
| US-7714018-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090253748-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2009-10-08 | — | — | US | disclosed |
| US-20090253748-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2009-10-08 | — | — | US | disclosed |
| US-20090209584-A1 | Antibacterial mutilins | NABRIVA THERAPEUTICS FORSCHUNGS AG (AT) | 2009-08-20 | — | — | US | disclosed |
| US-7569587-B2 | Antibacterial mutilins | NABRIVA THERAPEUTICS AG (AT) | 2009-08-04 | — | — | US | disclosed |
| WO-2008040043-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2008-04-10 | — | — | WO | disclosed |
| US-20070117859-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-05-24 | — | — | US | disclosed |
| US-7169804-B2 | Antibacterial mutilins | Nabriva Therapeutics GmbH (AT) | 2007-01-30 | — | — | US | disclosed |
| US-7164019-B2 | Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC | ROCHE PALO ALTO LLC (US) | 2007-01-16 | — | — | US | disclosed |
| US-20060014767-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723770-B2 | Crystal structure of the large ribosomal subunit from S. aureus | MRPS27, MRPS35, MRPS23 | DPP4 4374/4885DPP7 4034/4885DPP8 4043/4885 |
| US-20130053571-A1 | PLEUROMUTILINS AND PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | PLEC, MLN, PTMA | DPP4 1654/4885DPP7 1130/4885DPP8 3176/4885 |
| US-20090209584-A1 | Antibacterial mutilins | MRPS18B, MRPS27, MSRB3 | DPP4 3293/4885DPP7 2379/4885DPP8 3096/4885 |
| US-20060014767-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | DPP4 1952/4885DPP7 1919/4885DPP8 2056/4885 |
| US-20090253748-A1 | PROCESS FOR THE PREPARATION OF PLEUROMUTILINS | PLEC, MLN, PTMA | DPP4 2017/4885DPP7 1451/4885DPP8 3477/4885 |
| US-20200339635-A1 | CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM S. AUREUS | MRPS27, MRPS35, MRPS23 | DPP4 4374/4885DPP7 4034/4885DPP8 4043/4885 |
| US-20200131232-A1 | CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM S. AUREUS | MRPS27, MRPS35, MRPS23 | DPP4 4374/4885DPP7 4034/4885DPP8 4043/4885 |
| US-20180009853-A1 | CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM S. AUREUS | MRPS27, MRPS35, MRPS23 | DPP4 4374/4885DPP7 4034/4885DPP8 4043/4885 |
| US-10556934-B2 | Crystal structure of the large ribosomal subunit from S. aureus | MRPS27, MRPS35, MRPS23 | DPP4 4374/4885DPP7 4034/4885DPP8 4043/4885 |
| US-20070117859-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | DPP4 1952/4885DPP7 1919/4885DPP8 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.